

RECEIVED
CENTRAL FAX CENTER

Attorney Docket No.: 5994.504-US

SEP 23 2004

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ezban et al.

Serial No.: 10/051,044

Group Art Unit: 1653

Filed: January 14, 2002

Examiner: Holly G. Schnizer

Confirmation No.: 1706

For: Use of FVIIa or a Tissue Factor Antagonist for Regulating Gene Expression and Cell Migration or Chemotaxis

CERTIFICATE OF FACSIMILE TRANSMISSION
703-872-9306Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:


I hereby certify that the attached correspondence comprising:

1. Petition and Fees for Extension of Time (in duplicate)
2. Response to Office Action

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner Holly G. Schnizer at fax number (703) 872-9306 .

Respectfully submitted,

Date: September 24, 2004


Csaba Attila Szokolczai
Novo Nordisk® Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

RECEIVED
CENTRAL FAX CENTER

SEP 23 2004

Please use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE

Attorney Docket No.: 5994.504-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ezban et al.

Serial No.: 10/051,044

Group Art Unit: 1653

Filed: January 14, 2002

Examiner: Holly G. Schnizer

For: Use of FvIIa or A Tissue Factor Antagonist for
Regulating Gene Expression and Cell Migration
or Chemotaxis

RESPONSE TO OFFICE ACTION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action mailed March 25, 2004, please amend the above-captioned application as follows:

Amendments to the Claims are reflected in the **Listing of Claims**, which begins on page 2 of this paper.

Remarks concerning the Office Action and the claim amendments begin on page 4 of this paper.